GlassScriptPhysician profile
Latara Craddock
NPI 1942821152
$4,670.55
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $394 · 2022: $1,609 · 2023: $1,988 · 2024: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584 · Gift: $59.40 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,583.61 |
| Gift | $59.40 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,176.69 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $678.91 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $524.13 | 2021-2023 | Minimed 780g |
| Abbott Laboratories | $415.43 | 2021-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $256.92 | 2021-2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $215.41 | 2022-2023 | Omnipod |
| Sanofi-Aventis U.S. LLC | $211.10 | 2021-2023 | |
| Amgen INC. | $179.09 | 2022-2024 | Prolia, Evenity |
| Mannkind Corporation | $148.67 | 2023-2024 | Afrezza |
| Pfizer INC. | $104.24 | 2023-2024 | |
| Abbvie INC. | $92.06 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.18 | 2022-2024 | |
| Nevro Corp. | $78.20 | 2022-2023 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.33 | 2022-2023 | Jardiance |
| Cequr Corporation | $72.39 | 2024 | Cequr Simplicity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $61.17 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Astrazeneca Pharmaceuticals LP | $56.54 | 2022-2023 | Farxiga |
| Lifescan, INC. | $45.35 | 2023 | |
| Corcept Therapeutics | $35.99 | 2023 | Korlym |
| Xeris Pharmaceuticals, INC. | $29.01 | 2023 | Gvoke Hypopen |
| Beta Bionics, INC. | $28.21 | 2024 | Ilet Bionic Pancreas |
| Boston Scientific Corporation | $26.24 | 2024 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Glaxosmithkline, LLC. | $23.36 | 2024 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $15.86 | 2023 | |
| Horizon Therapeutics Plc | $11.69 | 2022 | |
| Clarus Therapeutics INC. | $3.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latara Craddock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.